In this week’s Pharma Phriday (April 17, 2026): In the clinic, some of the hardest-to-treat cancers are finally yielding ground, with survival data that would have been difficult to imagine a few years ago. Rare and underserved oncology and dermatology indications are also seeing regulatory progress. On the deals side, ADCs continue to attract serious investment, AI partnerships are expanding well beyond drug discovery into core business operations, and radiopharma is drawing

This week's edition of Pharma Phriday (April 10, 2026) spans late-stage clinical results in thyroid eye disease, achondroplasia, small cell lung cancer, hidradenitis suppurativa, macular degeneration, and inflammatory respiratory conditions; regulatory approvals and submissions in rare and chronic disease; and a flurry of M&A and partnership activity spanning oncology, rare disease, and drug delivery innovation.

We've had Eyes on several firms that are actively executing on their strategic plans to ensure competitiveness in their markets. Take a look at how BioNTech, Novo Nordisk, and Merck are adapting to changing markets and technologies.